NASDAQ:CRSP CRISPR Therapeutics (CRSP) News Today $64.52 +0.48 (+0.75%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$62.84▼$65.6050-Day Range$43.43▼$67.7752-Week Range$38.94▼$86.95Volume1.26 million shsAverage Volume1.23 million shsMarket Capitalization$5.09 billionP/E RatioN/ADividend YieldN/APrice Target$74.89 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Play video for Stocks Set to Rally this Summer CRSP Media Mentions By Week CRSP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.970.47▲Average Medical News Sentiment CRSP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼215▲CRSP Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBarclays Maintains CRISPR Therapeutics (CRSP) Equal-Weight Recommendationmsn.com - June 1 at 1:34 PMBarclays Increases CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $64.00americanbankingnews.com - June 1 at 8:48 AMAnalysts Conflicted on These Healthcare Names: Phreesia (PHR), Crispr Therapeutics AG (CRSP) and Ascendis Pharma (ASND)markets.businessinsider.com - June 1 at 8:33 AMQ2 2023 Earnings Estimate for CRISPR Therapeutics AG (NASDAQ:CRSP) Issued By William Blairamericanbankingnews.com - June 1 at 8:10 AMCRISPR Therapeutics AG (NASDAQ:CRSP) Sees Significant Decline in Short Interestamericanbankingnews.com - June 1 at 7:22 AMFranklin Resources Inc. Decreases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - June 1 at 6:43 AMWilliam Blair Begins Coverage on CRISPR Therapeutics (NASDAQ:CRSP)americanbankingnews.com - June 1 at 2:58 AMCRISPR Therapeutics AG Forecasted to Post Q1 2024 Earnings of ($2.18) Per Share (NASDAQ:CRSP)americanbankingnews.com - May 31 at 7:24 AMRaymond James & Associates Boosts Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - May 31 at 4:58 AMWilliam Blair Reiterates CRISPR Therapeutics (CRSP) Outperform Recommendationmsn.com - May 30 at 7:04 PMCRISPR Therapeutics (NASDAQ:CRSP) shareholders are still up 11% over 1 year despite pulling back 3.8% in the past weekfinance.yahoo.com - May 30 at 2:03 PMHighTower Advisors LLC Has $1.23 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - May 28 at 4:57 AMCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by CI Investments Inc.marketbeat.com - May 26 at 6:33 AMCRISPR Therapeutics Stock (NASDAQ:CRSP), Short Interest Reportbenzinga.com - May 25 at 7:15 PMQ2 2023 Earnings Forecast for CRISPR Therapeutics AG (NASDAQ:CRSP) Issued By Zacks Researchamericanbankingnews.com - May 25 at 6:23 AMCRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6.8% Following Analyst Upgradeamericanbankingnews.com - May 25 at 1:18 AMCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by FDx Advisors Inc.marketbeat.com - May 24 at 6:20 AMCitigroup Maintains CRISPR Therapeutics (CRSP) Neutral Recommendationmsn.com - May 24 at 12:14 AMCRISPR Therapeutics Unusual Options Activitybenzinga.com - May 23 at 7:14 PMCRISPR Therapeutics Earnings Perspective: Return On Capital Employedmsn.com - May 23 at 2:13 PMCRISPR Therapeutics Stock Joins Rank Of Stocks With RS Ratings Over 90finance.yahoo.com - May 23 at 2:13 PMNEA Management Company LLC Has $64.55 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - May 23 at 1:04 PMCRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $70.00 at Citigroupamericanbankingnews.com - May 23 at 8:05 AMCrispr Therapeutics: Hold Until A Firmer Decision Dateseekingalpha.com - May 19 at 10:32 AMCalifornia Public Employees Retirement System Sells 12,783 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - May 19 at 5:19 AMVertex Pharmaceuticals Hits Record High on Strong Q1 Earnings (CRSP)marketbeat.com - May 18 at 8:35 AMCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 5.3%americanbankingnews.com - May 18 at 7:18 AMCRISPR Therapeutics (NASDAQ:CRSP) Trading Up 5.3%americanbankingnews.com - May 17 at 8:02 AMCommonwealth Equity Services LLC Has $2.08 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - May 17 at 5:12 AMStifel Nicolaus Remains a Hold on Crispr Therapeutics AG (CRSP)markets.businessinsider.com - May 16 at 10:25 PMBedell Frazier Investment Counseling LLC Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - May 16 at 12:34 PMCantor Fitzgerald Weighs in on CRISPR Therapeutics AG's FY2023 Earnings (NASDAQ:CRSP)americanbankingnews.com - May 16 at 3:54 AMWhy Are CRISPR Therapeutics Charts Saying 'Buy'?realmoney.thestreet.com - May 16 at 3:40 AMCRISPR Therapeutics AG (CRSP) JMP Securities Life Sciences Conference (Transcript)seekingalpha.com - May 15 at 1:48 PMCRISPR Therapeutics AG (CRSP) Presents at JMP Securities Life Sciences Conference (Transcript)seekingalpha.com - May 15 at 1:48 PMCRISPR Therapeutics AG (NASDAQ:CRSP) to Post FY2023 Earnings of ($8.17) Per Share, Cantor Fitzgerald Forecastsmarketbeat.com - May 15 at 3:44 AMCRISPR Therapeutics (NASDAQ:CRSP) Upgraded at StockNews.comamericanbankingnews.com - May 14 at 5:36 AMChardan Capital Analysts Decrease Earnings Estimates for CRISPR Therapeutics AG (NASDAQ:CRSP)americanbankingnews.com - May 14 at 3:20 AMCRISPR Therapeutics AG (CRSP) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)seekingalpha.com - May 13 at 7:08 PMCRISPR Therapeutics AG (CRSP) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)seekingalpha.com - May 13 at 7:08 PMQ2 2023 Earnings Estimate for CRISPR Therapeutics AG Issued By Brookline Capital Management (NASDAQ:CRSP)americanbankingnews.com - May 13 at 3:22 AMCRISPR Therapeutics' (CRSP) "Reiterates" Rating Reaffirmed at VNET Groupamericanbankingnews.com - May 13 at 1:38 AMMorgan Stanley Maintains CRISPR Therapeutics (CRSP) Underweight Recommendationmsn.com - May 12 at 3:54 PMChardan Capital Analysts Reduce Earnings Estimates for CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - May 12 at 9:40 AMNordea Investment Management AB Has $4.05 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - May 12 at 5:49 AMEquities Analysts Set Expectations for CRISPR Therapeutics AG's FY2024 Earnings (NASDAQ:CRSP)americanbankingnews.com - May 12 at 5:04 AMVan ECK Associates Corp Acquires 14,084 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)marketbeat.com - May 11 at 6:33 AMCRISPR Therapeutics AG (NASDAQ:CRSP) Receives $72.84 Average PT from Brokeragesamericanbankingnews.com - May 11 at 2:38 AMRBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)markets.businessinsider.com - May 10 at 6:03 PMThis Is What Whales Are Betting On CRISPR Therapeuticsbenzinga.com - May 10 at 6:03 PM Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vaxcyte News Halozyme Therapeutics News Denali Therapeutics News Exelixis News Abcam News Vir Biotechnology News Ginkgo Bioworks News Krystal Biotech News Immunovant News Revolution Medicines News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:CRSP) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.